Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes drug aims to improve daily glucose control

NCT ID NCT07215312

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests a new medicine called LY3938577 against a standard insulin (degludec) in 100 adults with type 2 diabetes who already use basal insulin. The goal is to see if the new drug helps keep blood sugar in a healthy range more safely and effectively over about 26 weeks. Participants must have an HbA1c between 7.5% and 10.5% and a BMI under 35.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have type 2 diabetes * Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening * Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive * Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2) Exclusion Criteria: * Have type 1 diabetes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus hyperglycemia hypoglycemia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

Contacts and locations

Locations

  • AMR Clinical

    Norman, Oklahoma, 73069, United States

  • Accellacare - Wilmington

    Wilmington, North Carolina, 28401, United States

  • CIPREC

    Buenos Aires, C1119ACN, Argentina

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Buenos Aires, C1425AGC, Argentina

  • Chrysalis Clinical Research

    St. George, Utah, 84790, United States

  • Cicemo Srl

    Buenos Aires, 1424, Argentina

  • Clinical Research of Central Florida

    Lakeland, Florida, 33805, United States

  • Consano Clinical Research, LLC

    Shavano Park, Texas, 78231, United States

  • Encompass Clinical Research

    Spring Valley, California, 91978, United States

  • Encore Medical Research

    Hollywood, Florida, 33024, United States

  • Encore Medical Research - Weston

    Weston, Florida, 33331, United States

  • Holston Medical Group

    Bristol, Tennessee, 37620, United States

  • Instituto Centenario

    CABA, 1204, Argentina

  • Instituto Médico Catamarca IMEC

    Rosario, 2000, Argentina

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, Iowa, 50266, United States

  • Juno Research

    Houston, Texas, 77040, United States

  • Mautalen Salud e Investigación

    Buenos Aires, C1128AAF, Argentina

  • Southern Endocrinology Associates

    Mesquite, Texas, 75149, United States

  • Tampa Bay Medical Research

    Clearwater, Florida, 33761, United States

  • Texas Diabetes & Endocrinology, P.A.

    Austin, Texas, 78749, United States

  • Texas Valley Clinical Research

    Weslaco, Texas, 78596, United States

  • Tribe Clinical Research, LLC

    Greenville, South Carolina, 29607, United States

  • Tucson Clinical Research Institute

    Tucson, Arizona, 85712, United States

  • University Clinical Investigators, Inc.

    Tustin, California, 92780, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.